Rezolute, Inc.

NASDAQ:RZLT

Biotechnology

Healthcare
$4.25 +6.16%

+$0.30 today

Market cap
$411.10M
Beta
0.65
P/E (TTM)
-6.5
EPS (TTM)
-$0.78
52W Low $1.07High $11.46

Volume 2.93M

Average 2.03M

RZLT Other Non-current Assets

Long-term assets not reported separately.

Rezolute, Inc.NASDAQ: RZLT

Other Non-current Assets · Q3 FY2026 · quarter ended Mar 2026

Other non-current assets falls 16.5% from a year ago

Other non-current assets stood at $2.44M at the end of Q3 FY2026, down 16.5% from a year earlier and up 1.7% from the prior quarter. Over 3 fiscal years it compounded at +170.4% a year.

Context

  • Other non-current assets amounted to 1.9% of total assets at the end of Q3 FY2026, down 1.1 pp from a year earlier.
  • Other non-current assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current assets keeps falling in the next quarterly balance sheet after a -16.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.44M+1.7% QoQ
Last fiscal yearJun 2025
$2.93M+59.1% YoY
Year agoMar 2025
$2.93M-16.5% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.5%——
1 year+59.1%——
3-year CAGR+170.4%——
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
2.93M USD
Year-over-year change
+59.1%
4-year CAGR
+97.8%

Other Non-current Assets vs competitors

How RZLT compares with its peers on the latest reported figures

  • RZLT's Mar 2026 other non-current assets of $2.44M is the 2nd highest of the 5 companies compared; the peer median is $476.5K.
  • Its year-over-year change of -16.5% is the 2nd highest of 4, against a peer median of -94.5%.
  • Other non-current assets amounts to 1.9% of total assets for RZLT, versus a peer median of 0.8%.
RZLT Competitors Peer median
Other Non-current Assets for RZLT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$55M -11.8%-10.2%4.2%
RZLTRezolute, Inc.Mar 2026$2.44M -16.5%+170.4%1.9%
RLYBRallybio CorporationMar 2026$810K ——1.5%
ZVRAZevra Therapeutics, Inc.Mar 2026$143K -98.7%+12.2%0.1%
PHARPharming Group N.V.Mar 2026$92K -94.5%-58.6%0.0%
Peer median (excluding RZLT) $476.5K-94.5%-10.2%0.8%

Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Cash & Equivalents41.05M150.41M16.04M70.4M94.11M
Short-term Investments0085.86M56.48M73.75M
Net Receivables00000
Inventory00000
Other Current Assets0001.78M3.29M
Total Current Assets41.99M152.1M104.91M128.65M171.15M
Property, Plant & Equipment (Net)425K168K2.19M1.98M1.42M
Goodwill00000
Intangible Assets00000
Long-term Investments0016.47M263K0
Tax Assets00000
Other Non-current Assets191K148K148K1.84M2.93M
Total Non-current Assets616K316K18.81M4.08M4.35M
Total Assets42.61M152.42M123.72M132.74M175.49M
Account Payables1.04M1.13M3.27M4.9M5.81M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities77K0883K1.81M2.27M
Total Current Liabilities1.97M2.46M5.2M9.61M11.91M
Long-term Debt13.97M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities387K407K412K468K468K
Total Non-current Liabilities14.54M487K2.35M2.13M1.45M
Total Liabilities16.51M2.95M7.55M11.73M13.36M
Common Stock8K34K37K53K87K
Retained Earnings(168.14M)(209.2M)(260.99M)(329.44M)(403.86M)
Accumulated OCI00(351K)(79K)(7K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity26.1M149.47M116.17M121M162.13M
Total Debt14.42M188K2.48M2.23M1.62M
Net Debt(26.63M)(150.22M)(13.56M)(68.17M)(92.49M)

Rezolute, Inc.

NASDAQ:RZLT

Intrinsic Alpha fair value

Locked

Current Price

$4.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.